<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401035</url>
  </required_header>
  <id_info>
    <org_study_id>B1791089</org_study_id>
    <secondary_id>2014-002182-29</secondary_id>
    <secondary_id>B1791089</secondary_id>
    <secondary_id>GERD</secondary_id>
    <nct_id>NCT02401035</nct_id>
  </id_info>
  <brief_title>PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects</brief_title>
  <official_title>AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS OF SINGLE AND MULTIPLE INTRAVENOUS DOSES OF PANTOPRAZOLE IN TWO AGE COHORTS OF HOSPITALIZED PEDIATRIC SUBJECTS 1 TO 16 YEARS OF AGE WHO ARE CANDIDATES FOR ACID SUPPRESSION THERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the pharmacokinetics (PK) and safety of
      intravenous (IV) pantoprazole in patients 1 to 16 years old who are candidates for acid
      suppression therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In hospitalized pediatric subjects, age 1 to 16 years who in the judgment of the investigator
      are candidates for acid suppression therapy, the following are the objectives of this trial:

      Primary Objectives To characterize the PK of single and multiple IV doses of pantoprazole in
      pediatric subjects aged 1 to less than 2 years old.

      To characterize the PK of single and multiple IV doses of pantoprazole in pediatric subjects
      aged 2 to 16 years old.

      Secondary Objectives To determine the safety, tolerability, and PK of single and multiple IV
      doses of pantoprazole in each of the independent age cohorts.

      To assess the CYP2C19 genotype in pediatric subjects receiving IV pantoprazole, to determine
      the presence of the gene for the major enzyme responsible for metabolism of pantoprazole.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2017</start_date>
  <completion_date type="Anticipated">May 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of distribution of IV pantoprazole</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of IV pantoprazole</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution of IV pantoprazole</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of IV pantoprazole</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CYP2C19 genotyping</measure>
    <time_frame>Day 1</time_frame>
    <description>CYP2C19 genotyping will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time profile from 0 to 24 hours</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time profile from 0 to 24 hours</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time profile from time 0 extrapolated to infinite time</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under plasma concentration-time profile from time 0 extrapolated to infinite time</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>Day 1</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>Day 2</time_frame>
    <description>Pharmacokinetic parameters will be summarized descriptively</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>IV pantoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV pantoprazole</intervention_name>
    <description>Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight</description>
    <arm_group_label>IV pantoprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 1 to 16 years who in the judgment of the investigator are candidates for
             gastric acid suppression therapy (ie, those with a presumptive diagnosis of GERD, a
             clinical diagnosis of suspected GERD, symptomatic GERD, or endoscopically proven GERD)
             and whom the investigator judges would need to receive IV PPI therapy for at least 4
             days.

          -  Body weight &gt; 5th percentile for age.

          -  Y-site or dedicated IV line for administration of pantoprazole sodium.

          -  Expected survival for at least 30 days.

          -  Fertile male and female subjects of childbearing potential at risk for pregnancy must
             agree to use a highly effective method of contraception throughout the study and for
             at least 28 days after the last dose of assigned treatment. Female subjects of
             non-childbearing potential must be premenarchal, have undergone hysterectomy with
             bilateral oophorectomy, have medically confirmed ovarian failure, or achieved
             post-menopausal status.

        Exclusion Criteria:

          -  Participation in other studies involving investigational drug(s) or treatment with an
             investigational drug within 30 days or 5 half lives prior to study entry and/or during
             study participation.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.

          -  Pregnant females; breastfeeding females; fertile male subjects, and female subjects of
             childbearing potential who are unwilling or unable to use a highly effective method of
             contraception for the duration of the study and for at least 28 days after last dose
             of investigational product.

          -  Serum CK levels &gt;3x ULN.

          -  Known history of HIV or clinical manifestations of AIDS.

          -  Known hypersensitivity to PPIs or to any substituted benzimidazole or to any of the
             excipients.

          -  History of treatment with any PPI within 2 days (48 hours) before investigational
             product dosing on Day 1.

          -  Use of H2RAs, sucralfate, misoprostol, or prokinetic agents, and bismuth preparations
             within 1 day (24 hours) before investigational product dosing on Day 1.

          -  Any disorder requiring chronic (every day) use of warfarin, carbamazepine, or
             phenytoin, methotrexate, atazanavir or nelfinavir, clopidogrel, and potent inhibitors
             and inducers of CYP2C19.

          -  Chronic (daily) use of glucocorticoids. Steroid inhalers and topical steroids may be
             used.

          -  Active malignancy of any type, or history of a malignancy (Subject with a history of
             malignancies that have been surgically removed or eradicated by irradiation or
             chemotherapy and who have no evidence of recurrence for at least 5 years before
             Screening are acceptable).

          -  ALT or BUN &gt;2.0 ULN or estimated creatinine &gt;1.5 X ULN for age or any other laboratory
             abnormality considered by the Investigator to be clinically significant within 14 days
             before Screening.

          -  In the Investigator's opinion, a chronic condition (eg, diabetes, epilepsy), which is
             either not stable or well controlled and may interfere with the conduct of the study.

          -  History of sensitivity to heparin or heparin induced thrombocytopenia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center / New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Morgan Stanley Children's Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Health Specialty Center Dallas Campus</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. Ignacio Pirovano</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>1430</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Militar Central &quot;Cirujano Mayor Dr. Cosme Argerich&quot;</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1426BOS</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University clinical center of the Republic of Srpska</name>
      <address>
        <city>Banja Luka</city>
        <zip>78000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University clinical center Sarajevo</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>JSC Evex Medical Corporation</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Imedi Clinic</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum im St. Josef-Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zentralapotheke St. Joseph Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II di Napoli Servizio di Endoscopia</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Farmacia - AOU Federico II di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Trials - Dipartimento Pediatrico Universitario Ospedaliero Padiglione Salviati</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS-Ospedale Pediatrico Bambino Gesù Farmacia Ospedaliera</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for mother and child healthcare dr Vukan Cupic</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center Nis</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Child and Youth Health Care of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Detska fakultna nemocnica s poliklinikou Bratislava</name>
      <address>
        <city>Bratislava</city>
        <zip>833 40</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Martin</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bosnia and Herzegovina</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1791089</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 15, 2014</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>candidate for acid suppression therapy</keyword>
  <keyword>presumptive diagnosis of GERD</keyword>
  <keyword>clinical diagnosis of suspected GERD</keyword>
  <keyword>symptomatic GERD</keyword>
  <keyword>endoscopically proven GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

